We are live on ! Find out more

Onconetix

ONCO

Market cap $3.37M

0.7690 USD

-0.3410

30.72%

At close Updated Sep 29, 3:09 PM EDT

1 day

-30.72%

5 days

17.4%

1 month

22.69%

3 months

-19.42%

6 months

-95.1%

Year to date

-99.04%

1 year

-99.52%

5 years

-100%

10 years

-100%

About: Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.

Employees: 2

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition

Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition

Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events

Pilot Tests Humanoid Robots as Presenters, Hosts, and Brand Ambassadors Before Live Audiences, Extending Robot Capabilities Beyond One-on-One Interaction into Dynamic, Audience-Facing Environments; Onconetix Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.

Onconetix Acquisition Target Realbotix Launches Pilot with Leading European Telecommunications Company to Deploy Humanoid Robots in Live Presentations and Events

Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series

Entertainment Industry Agreement Reflects Real-World Adoption of Humanoid Robotics Technology Across Education, Healthcare, Hospitality, and Customer Engagement; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix's previously announced pending acquisition. Realbotix has entered into an agreement with a recognized streaming platform to feature one of its humanoid robots as a robotic character in an upcoming episode of a popular Emmy-awarded television series.

Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series

Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG

Proteomedix Co-Founder and Proclarix® Co-Developer Returns to Company's Board; Thomas Meier, PhD Re-Elected as Chairman at Annual General Meeting CINCINNATI, Ohio , Aug. 05, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that its fully-owned Swiss subsidiary, Proteomedix AG (“PMX”), has appointed Ralph Schiess, PhD to the PMX Board of Directors. The appointment was approved at the PMX Annual General Meeting of Shareholders held on June 22, 2026, at which Thomas Meier, PhD was also re-elected to serve an additional one-year term as Chairman of the Board.

Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom's Public Sector Marketplace; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp. CINCINNATI, Ohio, July 07, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) is providing the following summary of a press release issued by Realbotix Corp., parent of Realbotix LLC (“Realbotix”), the target of Onconetix's previously announced pending acquisition. Realbotix has announced a partnership with Bloom Procurement Services (“Bloom”), a UK public sector procurement specialist, to launch a pilot program deploying socially assistive humanoid robots to combat loneliness and improve wellbeing among elderly residents in Northeast England.

Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation

Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District

Salamanca City Central School District on Seneca Nation Reservation to Deploy Optio and Realbotix M-Series Humanoid Robot; Pilot to Expand to Approximately 500 High School Students in Fall 2026; Onconetix Recently Entered into a Definitive Agreement to Acquire Realbotix LLC, a Subsidiary of Realbotix Corp.

Onconetix Highlights Realbotix's Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District

Onco-Innovations Announces Non-Brokered LIFE Offering

Not for distribution to United States wire services or for dissemination in the United States VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE:ONCO) ("Onco" or the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "Private Placement") of units of the Company (each, a "Unit"), pursuant to which it will offer 6,764,069 Units at a price of CAD$0.7392 per Unit for aggregate gross proceeds of approximately CAD$5,000,000 pursuant to the Listed Issuer Financing Exemption (as defined below). Each Unit is comprised of one common share (each a "Share") and one common share purchase warrant (a "Warrant"), with each Warrant entitling the holder to purchase one Share at a price of CAD$0.90 for a period of three years following the closing date of the Private Placement, which is expected to occur on or about July 10, 2026, subject to certain conditions, including the receipt of all necessary regulatory approvals, including the approval of Cboe Canada Inc. (the "Cboe").

Onco-Innovations Announces Non-Brokered LIFE Offering

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

Also Announces Appointment of Mr. Dave Antony as CFO VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN:A3EKSZ) ("Onco" or the "Company") announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient ("API") underpinning the Company'sproprietary drug candidate, ONC010 (the "PNKP Inhibitor Technology").

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization

VANCOUVER, BC / ACCESS Newswire / June 16, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated November 18, 2025, the completion of its pilot project with Kuano Ltd. ("Kuano"), supporting the continued advancement of Onco's PNKP Inhibitor Technology (also known as ONC010) through advanced AI-enabled and quantum-based computational approaches.

Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization

See News Rankings

Price charts implemented using Lightweight Charts™